Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Working Capital Changes: 2009-2025

Historic Other Working Capital Changes for Aytu Biopharma (AYTU) over the last 14 years, with Sep 2025 value amounting to $4,818.

  • Aytu Biopharma's Other Working Capital Changes rose 104.05% to $4,818 in Q3 2025 from the same period last year, while for Sep 2025 it was $4,818, marking a year-over-year increase of 102.74%. This contributed to the annual value of $5,078 for FY2025, which is 63.12% up from last year.
  • Aytu Biopharma's Other Working Capital Changes amounted to $4,818 in Q3 2025, which was up 100.17% from -$2.9 million recorded in Q2 2025.
  • Aytu Biopharma's Other Working Capital Changes' 5-year high stood at $8.0 million during Q2 2021, with a 5-year trough of -$5.9 million in Q1 2021.
  • Moreover, its 3-year median value for Other Working Capital Changes was -$41,000 (2024), whereas its average is -$301,286.
  • As far as peak fluctuations go, Aytu Biopharma's Other Working Capital Changes slumped by 350,100.00% in 2024, and later spiked by 4,129.27% in 2025.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Other Working Capital Changes stood at $2.2 million in 2021, then grew by 28.97% to $2.8 million in 2022, then slumped by 102.17% to -$61,000 in 2023, then surged by 1,408.20% to $798,000 in 2024, then surged by 104.05% to $4,818 in 2025.
  • Its last three reported values are $4,818 in Q3 2025, -$2.9 million for Q2 2025, and $1.7 million during Q1 2025.